Bariatric surgery, gastrointestinal hormones, and the microbiome: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022

Obesity, thrombosis, venous disease, lymphatic disease, and lipedema: An obesity medicine association (OMA) clinical practice statement (CPS) 2023

“…On a more chronic postoperative basis in patients treated for obesity, weight reduction via bariatric surgery reduces venous thromboembolic risk, mainly due to a reduction in deep vein thrombosis [ 93 ]. In addition to other health benefits [ 22 ], bariatric surgery improves many of the risk factors for thrombosis as described in Section 2 . Among the more important effects of bariatric surgery are a less vascular compression and venous stasis due to a reduction in fat mass impairment of blood flow (see Fig.…”

“…In addition to Obesity Medicine Association (OMA) Position Statements [ 1 , 2 ], the OMA has published a series of Clinical Practice Statements, reviews, and round-table discussions regarding obesity-related diagnostic and treatment consideration of cardiometabolic topics such as nutrition [ 3 ], physical activity [ 3 ], pediatrics [ [4] , [5] , [6] ], race/ethnicities [ [7] , [8] , [9] , [10] ], body composition [ 11 , 12 ], behavior modification [ 13 ], anti-obesity medications [ [14] , [15] , [16] ], concomitant medications [ 17 ], diabetes mellitus [ 18 ], hypertension [ 19 ], mental stress [ 20 ], sleep apnea [ 21 ], and bariatric surgery [ 22 ]. This OMA Clinical Practice Statement explores the relationship between obesity and thrombosis, venous disease, lymphatic disease, and lipedema.…”

Established and potential cardiovascular risk factors in metabolic syndrome: Effect of bariatric surgery

“…This improvement is primarily driven by caloric restriction, reduction of liver fat, improved hepatic insulin sensitivity and enhanced insulin clearance by the liver [110]. Other possibilities include enhanced beta cell function, reduced gluconeogenesis, changes in gut hormones and the microbiome response [107,108]. Long-term improvements and remission from diabetes are achieved through progressive fat mass loss and improved peripheral insulin sensitivity.…”

“…Other nonlipoprotein biomarkers of metabolic syndrome are summarized in Table 2[83–90,91 ▪ ,92,93–100,101 ▪ ,102,103–107].…”

Obesity pillars roundtable: Phentermine – Past, present, and future

“…More robust research is needed to determine the right treatment for the right patient in the right combination for the most optimal outcome. This also includes how to combine endoscopic procedures and bariatric surgery with adjuvant pharmaceutical therapy [ 10 , 44 ], much like we do with cancer treatment today.…”